User menu

[Challenges and Strategies for Moving Patients to Injectable Medications]

Bibliographic reference Hermans, MP. ; Buysschaert, Martin ; Gala, Jean-Luc. [Challenges and Strategies for Moving Patients to Injectable Medications].In: Diabetes & Metabolism, Vol. 32, p. S82-S83 (2006)
Permanent URL
  1. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, 10.1056/nejm199309303291401
  2. UK Prospective Diabetes Study (UKPDS) Group. JAMA, 281, 2005 (1999)
  3. State of diabetes in America
  4. , Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial, 10.2337/diacare.11.7.567
  5. Salle A., Guilloteau G., Ryan M., Bouhanick B, Ritz P., Effect of insulin treatment on the body composition of Type 2 diabetic patients, 10.1111/j.1464-5491.2004.01335.x
  6. Leese G. P., Wang J., Broomhall J., Kelly P., Marsden A., Morrison W., Frier B. M., Morris A. D., Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes: A population-based study of health service resource use, 10.2337/diacare.26.4.1176
  7. , Hypoglycemia in the Diabetes Control and Complications Trial, 10.2337/diab.46.2.271
  8. Purnell Jonathan Q., Hokanson John E., Marcovina Santica M., Steffes Michael W., Cleary Patricia A., Brunzell John D., Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure : Results From the DCCT, 10.1001/jama.280.2.140
  9. Cryer P. E., Davis S. N., Shamoon H., Hypoglycemia in Diabetes, 10.2337/diacare.26.6.1902
  10. Kolotkin Ronette L., Crosby Ross D., Williams G.Rhys, Assessing weight-related quality of life in obese persons with type 2 diabetes, 10.1016/s0168-8227(03)00113-x
  11. Int J Clin Pract Suppl., 129, 20 (2002)
  12. Diabetologia, 46, A274 (2003)
  13. Shah B. R., Hux J. E., Laupacis A., Zinman B., van Walraven C., Clinical Inertia in Response to Inadequate Glycemic Control: Do specialists differ from primary care physicians?, 10.2337/diacare.28.3.600
  14. Nurse Pract., 29, 11 (2004)
  15. Lantus®: insulin glargine [rDNA origin] injection
  16. Buse J. B., Henry R. R., Han J., Kim D. D., Fineman M. S., Baron A. D., , Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes, 10.2337/diacare.27.11.2628
  17. DeFronzo R. A., Ratner R. E., Han J., Kim D. D., Fineman M. S., Baron A. D., Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes, 10.2337/diacare.28.5.1092
  18. Kendall D. M., Riddle M. C., Rosenstock J., Zhuang D., Kim D. D., Fineman M. S., Baron A. D., Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea, 10.2337/diacare.28.5.1083
  19. Riddle Matthew C., Making the transition from oral to insulin therapy, 10.1016/j.amjmed.2005.04.008
  20. Riddle M. C., Rosenstock J., Gerich J., The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, 10.2337/diacare.26.11.3080
  21. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R. A., Hu P., Bode B., Garber A., , Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs, 10.2337/diacare.28.2.260
  22. Feinglos M. N., Thacker C. H., English J., Bethel M. A., Lane J. D., Modification of Postprandial Hyperglycemia With Insulin Lispro Improves Glucose Control in Patients With Type 2 Diabetes, 10.2337/diacare.20.10.1539
  23. Diabetes Res Clin Pract., 68, S30 (2005)
  24. Ryan E. A., Imes S., Wallace C., Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes, 10.2337/diacare.27.5.1028
  25. Rubin Richard R., Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus, 10.1016/j.amjmed.2005.04.012
  26. Diabetes, 54, A4 (2005)
  27. J Fam Pract., 54, S3 (2005)
  28. , U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease, 10.2337/diab.44.11.1249
  29. United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy, 10.7326/0003-4819-128-3-199802010-00001
  30. Fineman Mark S., Shen Larry Z., Taylor Kristin, Kim Dennis D., Baron Alain D., Effectiveness of progressive dose-escalation of exenatide(exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes, 10.1002/dmrr.499
  31. Diabetes Care, 54, A118 (2005)
  32. Wilson Marianne, Moore M.Peter, Lunt Helen, Treatment satisfaction after commencement of insulin in Type 2 diabetes, 10.1016/j.diabres.2004.04.010
  33. Mollema E.D, Snoek F.J, Adèr Herman J, Heine R.J, van der Ploeg H.M, Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing, 10.1016/s0022-3999(01)00229-x
  34. Int J Obes Relat Metab Disord., 26, S18 (2002)
  35. Siminerio L., Zgibor J., Solano F. X., Implementing the Chronic Care Model for Improvements in Diabetes Practice and Outcomes in Primary Care: The University of Pittsburgh Medical Center Experience, 10.2337/diaclin.22.2.54
  36. American Association of Diabetes Educators 32nd Annual Meeting and Exhibition
  37. Annahern JO, Kruger Davida F., Gatcomb Patricia M., Petit William A., Tamborlane William V., The Diabetes Control and Complications Trial (DCCT): The Trial Coordinator Perspective : Report by the DCCT Research Group, 10.1177/014572178901500313
  38. Delahanty Linda, Simkins Sari W, Camelon Kathryn, Expanded role of the dietitian in the diabetes control and complications trial: Implications for clinical practice, 10.1016/0002-8223(93)91748-f
  39. Diabetes in America, 541 (1995)
  40. Endocr Practice, 12, 124 (2006)